The Resources in Your Lab
Someone Needs Right Now.
Every compound library, synthesis outflow, and failed lead holds scientific value — even when the original experiment didn't pan out. Bridge BioHealth connects biotech labs, pharma teams, and organic synthesis labs to share resources, exchange knowledge, and build a collaborative workflow from theory to synthesis.
Spotlight Resources
Hand-picked high-value listings from verified institutions
Cryo-EM Time — 200kV FEI Talos Arctica, UCSF
Booking slots available on a 200kV FEI Talos Arctica. Includes sample prep support, data collection, and basic processing pipeline. Minimum 8-hour blocks.
Bridge BioHealth is a connection-only platform. We do not take custody of, store, ship, or handle any materials, compounds, biological agents, data, or intellectual property. All transactions, transfers, and agreements are executed directly between the listing party and the requesting party. Bridge BioHealth assumes no liability for the quality, legality, or fitness of any listed resource.
Failed leads, synthesis outflows, IP trades & data exchanges — partnership opportunities, not just purchases.
High-Throughput Screening — Biochemical Assay Time
Access to fully automated HTS platform. 384-well format, fluorescence/luminescence readouts. Capacity for 50,000+ compounds per campaign. Turnaround 3-4 weeks.
Cold Chain Logistics — -80°C Biospecimen Transport
Validated -80°C dry ice and liquid nitrogen transport for biospecimens, cell lines, and biologics. GDP-compliant. Real-time temperature monitoring. 48-hour nationwide delivery.
Synthesis Outflow — 12kg Heterocyclic Intermediates
Excess synthesis intermediates from a discontinued oncology program — 12kg of high-purity heterocyclic scaffolds (pyrimidines, indazoles, triazines). Purity >98% by NMR/HPLC. Full characterization data available. Ideal for fragment-based screening or scaffold hopping.
Compound Library — 2,400 Diverse Small Molecules
Curated library of 2,400 diverse small molecules with full ADMET profiling. Includes natural products, diversity sets, and privileged scaffolds. Ideal for phenotypic and target-based screens. SDF files, IC50 data, and target annotations included.
GLP Toxicology Study Capacity — Rodent Models
Available capacity for GLP-compliant 28-day and 90-day rodent toxicology studies. Rat and mouse models. Full histopathology, clinical chemistry, and TK analysis included.
Organic Synthesis Capacity — Custom Scaffold Library Build
Medicinal chemistry team available for custom scaffold library synthesis. Specializing in sp3-rich, 3D-diverse compound sets. Capacity for 50–500 analogs per campaign. Full NMR/MS characterization. Collaborative IP arrangements available.
Cryo-EM Microscope Time — 200kV FEI Talos
Booking slots available on 200kV FEI Talos Arctica cryo-EM. Includes sample prep support, data collection, and basic processing pipeline. Minimum 8-hour blocks.
Failed Lead Dataset — 380 Inactive Kinase Inhibitors
Curated negative dataset of 380 kinase inhibitor candidates that failed selectivity or toxicity screens. Full assay data, SAR annotations, and failure mode classification included. Invaluable for training ML models and avoiding known dead ends.
Phase I Clinical Site — 24-Bed Unit Available
Phase I unit with 24 beds, experienced nursing staff, and full PK/PD sampling capability. Healthy volunteer and patient studies. FDA-inspected facility. Rapid site activation.
Whole Genome Sequencing Dataset — 500 Patient Cohort
De-identified WGS data from 500-patient oncology cohort. Paired tumor/normal samples. Available for IP co-development or academic collaboration. IRB approved.
Synthesis Outflow — Chiral Building Blocks (200+ Compounds)
Excess chiral building blocks from asymmetric synthesis campaigns. 200+ enantiopure compounds including amino acid derivatives, chiral amines, and lactam scaffolds. ee >99% confirmed by chiral HPLC. Ideal for stereoselective drug discovery programs.
CRISPR Knockout Cell Lines — 24 Validated Lines
24 validated CRISPR knockout HEK293 and HeLa cell lines targeting metabolic pathway genes. Full characterization data included. MTA or IP co-development required.
Phase II/III Patient Recruitment Network — Oncology
Access to 45-site oncology patient recruitment network. Solid tumors and hematologic malignancies. IRB-approved protocols. Average enrollment rate 3.2 patients/site/month.
Negative Screening Data — GPCR Panel (45 Targets)
Comprehensive negative screening dataset across 45 GPCR targets. 1,200 compounds tested, all inactive at 10µM. Includes dose-response curves, counter-screen data, and selectivity profiles. Shared in exchange for complementary screening data.
Synthetic Peptide Library — 800 Custom Sequences
Library of 800 custom synthesized peptides targeting kinase domains. Purity >95% by HPLC. Available for collaborative research with co-authorship agreement.
Discontinued Program Assets — CNS Scaffold Series
Full asset package from a discontinued CNS program: 6 lead scaffolds, 240 analogs, in vitro BBB permeability data, rodent PK, and 28-day tox data. Program halted due to strategic pivot, not safety. IP available for licensing or co-development.
Mass Spectrometry Analysis — Metabolomics Service
Untargeted and targeted metabolomics using Orbitrap LC-MS/MS. Full bioinformatics pipeline included. Turnaround 2 weeks. Minimum 20 samples per batch.
Multi-Omics Dataset — Proteomics + Transcriptomics
Paired proteomics and bulk RNA-seq data from inflammatory bowel disease study. 120 samples, 3 timepoints. Fully annotated, QC-passed. Open access for non-commercial use.
From Theory to Synthesis —
Together.
Biotech labs, pharma teams, and organic synthesis labs don't have to work in silos. Share your positive results, your failed leads, and your synthesis outflows. Every data point — hit or miss — accelerates the field.
Failed Leads Are
Not Failures.
An inactive compound tells you exactly where the chemical space boundary is. A failed selectivity screen defines what your target won't tolerate. A discontinued program contains years of hard-won SAR knowledge that shouldn't disappear into a filing cabinet.
When labs share negative data, the entire field moves faster. Duplicate experiments get eliminated. Dead ends get mapped. Resources flow toward what actually works.
of drug discovery experiments are duplicated across labs
in compound libraries expire unused every year
faster hit-to-lead when negative data is shared
of synthesis intermediates are discarded without reuse
Who We're Calling In
Biotech Labs
Pharma Teams
Organic Synthesis Labs
Ready to Share What You Have?
Whether it's a compound library, a failed lead dataset, or 12kg of synthesis intermediates — list it here. Someone in the network needs exactly what you have.
Every Stage. Every Service.
One Platform.
From target identification to post-market surveillance — Bridge BioHealth connects you with the resources, services, and expertise you need at every stage of drug development. We are the connector. You execute.
Don't see your specific service?
Post a resource request and our team will actively search our network on your behalf — at no cost.
List. Match. Transact.
Three steps. Zero custody. Bridge BioHealth connects resource holders with resource seekers — then gets out of the way.
List Your Resource
Post your available compound libraries, datasets, equipment time, or synthesis outflows. Free to list — always. Our team reviews every submission within 24 hours.
Free to listReady to list your resource?
Free to post. Reviewed within 24 hours. No custody, no liability.
$2.4 Billion in Lab
Resources Sit Idle
Every Year.
Across academia and industry, compound libraries expire, sequencing capacity goes unused, and equipment sits dark between projects. Meanwhile, startups and researchers spend months searching for exactly what's gathering dust three buildings away.
BioShare Exchange is the infrastructure layer that connects supply with demand — transparently, efficiently, and at zero cost to list.